NEW HAVEN, Conn., July 13, 2017 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (Biohaven, NYSE: BHVN)
announced today that the company has received a Notice of Allowance
from the U.S. Patent and Trademark Office (USPTO) for its patent
application number 14/385551, which covers certain prodrugs of the
glutamate modulating agent riluzole. The patent application
also covers pharmaceutical compositions containing the prodrugs
and methods of treating cancer, including melanoma.
Biohaven's glutamate modulating prodrugs are being studied in
clinical trials and preclinical studies for the treatment of
patients with a number of severe diseases, including forms of
ataxia, obsessive-compulsive disorder (OCD), anxiety disorders, and
other neurologic diseases.
A prodrug is a compound that, after administration, is
metabolized in the body into an active drug. The prodrug design and
selection pathways pursued by Biohaven are intended to address
limitations of the active metabolite of a drug. Prodrugs can be
engineered to enhance absorption, optimize pharmacokinetic
properties and deliver a lower drug load to attenuate
dose-dependent side effects.
"We are happy to receive this Notice of Allowance from the USPTO
as we drive the development of our broad pipeline of innovative
therapies," said Vlad Coric, M.D.,
CEO of Biohaven. "We expect to continue building a robust
portfolio of patents around our glutamate modulating prodrugs,
covering both methods of use and composition of matter."
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
combined internal development and research with intellectual
property licensed from companies and institutions including
Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers, ALS Biopharma LLC and Massachusetts
General Hospital. Currently, Biohaven's lead development programs
include multiple compounds across its CGRP receptor antagonist and
glutamate modulation platforms. The company's common shares are
listed on the New York Stock Exchange and traded under the ticker
symbol BHVN. More information about Biohaven is available at
www.biohavenpharma.com.
Forward-Looking Statements
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of the Company's management. All
statements, other than statements of historical facts, included in
this press release, including statements regarding the Company's
development of glutamate modulating prodrugs and the Company's
plans to continue building a patent portfolio around its glutamate
modulating prodrugs, are forward-looking statements. The use of
certain words, including the words "believe," "continue" and "will"
and similar expressions are intended to identify forward-looking
statements. The Company may not actually achieve the plans and
objectives disclosed in the forward-looking statements and you
should not place undue reliance on the Company's forward-looking
statements. Various important factors could cause actual results or
events to differ materially from those that may be expressed or
implied by our forward-looking statements, including the
significant risks and uncertainties regarding the development of
biopharmaceutical product candidates and the potential limitations
of intellectual property protection that may be afforded by any
patents that are issued with respect to the Company's technology.
Additional important factors to be considered in connection with
forward-looking statements are described in the "Risk Factors"
section of the Company's Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission on June 16, 2017. The forward-looking statements are
made as of this date and the Company does not undertake any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
For further information, contact Dr. Vladimir Coric, the Chief Executive Officer
at Vlad.Coric@biohavenpharma.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/biohaven-receives-notice-of-allowance-from-us-patent-and-trademark-office-on-patent-application-for-glutamate-modulating-prodrugs-300487616.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.